Coronary heart disease in women: Hormone replacement therapy

  • Mary S. Beattie
  • Rita Redberg
Article
  • 34 Downloads

Opinion statement

  • For both primary and secondary prevention of coronary heart disease (CHD), it is prudent to use strategies that are of proven benefit and that do not harm patients. In all women, these strategies include lifestyle approaches such as smoking avoidance, proper nutrition, and regular exercise. Lipid-lowering and blood pressure control with pharmacotherapy are indicated in women who do not meet target lipid or blood pressure levels with lifestyle interventions. For women with CHD, aspirin, beta-blockers, and angiotensin-converting enzyme inhibitors should be considered. Widespread under-use of established preventive therapies has been documented in women. These interventions should be emphasized in clinical practice.

  • For secondary prevention of CHD in women, the American Heart Association (AHA) recommends against initiating hormone replacement therapy (HRT) based on studies that have shown no benefit and early harm. For patients with CHD already on HRT, the decision to continue or stop HRT should be based on established noncoronary benefits and risks and patient preference.

  • There are insufficient data to suggest that HRT should be initiated for the sole purpose of primary prevention of CHD.

  • Because the new AHA guidelines recommend placing significant weight on the noncardiac benefits and risks of HRT, it is important to become familiar with these noncardiac effects. It is also important to understand the evidence supporting the AHA’s decision to recommend placing relatively less weight on the cardiac effects of HRT.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Hulley S, Grady D, Bush T, et al.: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998, 280:605–613. This randomized controlled trial (HERS) of Prempro vs placebo is the largest published secondary prevention trial of HRT in women with CHD. The results showed no benefit of HRT in cardiac morbidity or mortality after 4 to 5 years.PubMedCrossRefGoogle Scholar
  2. 2.
    Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in post-menopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA 1995, 273:199–208.Google Scholar
  3. 3.
    Mendelsohn ME, Karas RH: The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999, 340:1801–1811.PubMedCrossRefGoogle Scholar
  4. 4.
    Jick H, Derby LE, Myers MW, et al.: Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996, 348:981–983.PubMedCrossRefGoogle Scholar
  5. 5.
    Daly E, Vessy MP, Hawkins MM, et al.: Risk of venous thromboembolism in user of hormone replacement therapy. Lancet 1996, 348:977–980.PubMedCrossRefGoogle Scholar
  6. 6.
    Grady D, Wenger N, Herrington D, et al.: Postmenopausal hormone therapy increases risk of venous thromboembolic disease—the Heart and Estrogen/ progestin Replacement Study. Ann Intern Med 2000, 132:689–696.PubMedGoogle Scholar
  7. 7.
    The Coronary Drug Project design and methods, and baseline results. Coronary Drug Project Research Group. Circulation 1973, 47(suppl 3):1–60.Google Scholar
  8. 8.
    Stampfer MJ, Willett WC, Colditz GA, et al.: A prospective study of postmenopausal estrogen therapy and coronary heart disease. N Engl J Med 1985, 313:1044–1049.PubMedCrossRefGoogle Scholar
  9. 9.
    Wilson PW, Garrison RJ, Castelli WP: Postmenopausal estrogen use, cigarette smoking, and cardiovascular mortality in women over 50. The Framingham Study. N Engl J Med 1985, 313:1038–1043.PubMedCrossRefGoogle Scholar
  10. 10.
    Grady D, Rubin SM, Petitti DB, et al.: Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992, 117:1016–1037.PubMedGoogle Scholar
  11. 11.
    Sullivan JM, Vander Zwaag R, Lemp GF, et al.: Postmenopausal estrogen use and coronary athersclerosis. Ann Int Med 1988, 108:358–363.PubMedGoogle Scholar
  12. 12.
    Matthews KA, Kuller LH, Wing RR, et al.: Prior to use of estrogen replacement therapy, are users healthier than nonusers? Am J Epidemiol 1996, 143:971–978.PubMedGoogle Scholar
  13. 13.
    Herrington DM, Reboussin DM, Brosnihan KB, et al.: Effects of estrogen replacement on the progression of coronary artery atherosclerosis. N Engl J Med 2000, 343:522–529. This randomized controlled trial (ERA) found no angiographic differences in 309 women randomized to Premarin, Prempro, or placebo.PubMedCrossRefGoogle Scholar
  14. 14.
    Grodstein F, Manson JE, Stampfer MJ: Postmenopausal hormone use and secondary prevention of coronary events in the Nurses’ Health Study. Ann Intern Med 2001, 135:1–8.PubMedGoogle Scholar
  15. 15.
    Heckbert SR, Kaplan RC, Weiss NS, et al.: Risk of recurrent coronary events in relation to use and recent initiation of postmenopausal hormone therapy. Arch Intern Med 2001, 161:1709–1713.PubMedCrossRefGoogle Scholar
  16. 16.
    Psaty B, Smith NL, Lemaitre RN, et al.: Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal myocardial infarction in postmenopausal women. JAMA 2001, 285:906–913.PubMedCrossRefGoogle Scholar
  17. 17.
    National Institutes of Health, National Heart, Lung, and Blood Institute. Women’s Health Initiative. URL: www.nhlbi.nih.gov/whi/hrt-en.htm; accessed December 14, 2001.Google Scholar
  18. 18.
    Mosca L, Collins P, Herrington DM, et al.: Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 2001, 104:499–503. This article includes the American Heart Association’s November 2001 guidelines regarding HRT and cardiovascular disease in women and the evidence supporting these guidelines.PubMedGoogle Scholar
  19. 19.
    The Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52705 women with breast cancer and 108411 women without breast cancer. Lancet 1997, 350:1047–1059.CrossRefGoogle Scholar
  20. 20.
    Scgairer C, Lubin J, Troisi R, et al.: Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 2000, 283:485–491.CrossRefGoogle Scholar
  21. 21.
    Ross R, Paganini-Hill A, Wan P, Pike M: Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000, 92:328–332.PubMedCrossRefGoogle Scholar
  22. 22.
    Simon JA, Hsia J, Cualey JA, et al.: Postmenopausal hormone therapy and risk of stroke: the Heart and Estrogen-progestin Replacement Study (HERS). Circulation 2001, 103:638–642.PubMedGoogle Scholar
  23. 23.
    Viscoli CM, Brass LM, Kernan WN, et al.: Estrogen after ischemic stroke: effect of estrogen replacement on risk of recurrent stroke and death in the Women’s Estrogen for Stroke Trial (WEST) [abstract]. Stroke 2001, 32:329.Google Scholar
  24. 24.
    Cushing KL, Weiss NL, Voigt LF, et al.: Risk of endometrial cancer in relation to use of low-dose unopposed estrogens. Obstet Gynecol 1998, 91:35–39.PubMedCrossRefGoogle Scholar
  25. 25.
    Grodstein F, Martinez E, Platz EA, et al.: Postmenopausal hormone use and risk of colorectal cancer and adenoma. Ann Intern Med 1998, 128:705–712.PubMedGoogle Scholar
  26. 26.
    Yaffe K, Sawaya G, Lieberburg I, Grady D, et al.: Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. JAMA 1998, 279:688–695.PubMedCrossRefGoogle Scholar
  27. 27.
    Mulnard R, Cotman C, Kawas C, et al.: Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease. JAMA 2000, 283:1007–1015.PubMedCrossRefGoogle Scholar
  28. 28.
    Torgerson DJ, Bell-Syer SE: Hormone replacement therapy and prevention of non-vertebral fractures: a meta-analysis of randomized trials. JAMA 2001, 285:2909–2910.CrossRefGoogle Scholar
  29. 29.
    Greendale G, Reboussin B, Hogan P, et al.: Symptom relief and side effects of postmenopausal hormones: results from the postmenopausal estrogen/progestin interventions trial. Obstet Gynecol 1998, 92:982–988.PubMedCrossRefGoogle Scholar
  30. 30.
    Stampfer MJ, Hu FB, Manson JE: Primary prevention of coronary heart disease in women through diet and lifestyle. N Engl J Med 2000, 343:16–22.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2002

Authors and Affiliations

  • Mary S. Beattie
    • 1
  • Rita Redberg
    • 1
  1. 1.Division of General Internal MedicineUniversity of California, San FranciscoSan FranciscoUSA

Personalised recommendations